Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.60 |
| ▸ | TAF1 | P21675 | 5/20 | 0.60 |
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.60 |
| ▸ | BRD4 | O60885 | 8/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753965 | 0.90 | BRD9 (0.72) | BRD9TAF1CECR2BRD4BCHE | |
| SCHEMBL17754077 | 0.84 | BRD9 (0.56) | BRD9TAF1CECR2BRD4BCHE | |
| SCHEMBL17749004 | 0.83 | TAF1 (0.55) | BRD9TAF1CECR2BRD4BCHE | |
| SCHEMBL17753899 | 0.82 | BRD9 (0.61) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17754174 | 0.81 | CECR2 (0.59) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17749030 | 0.81 | TAF1 (0.61) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17753966 | 0.80 | BRD9 (0.64) | BRD9TAF1CECR2BRD4BCHE | |
| SCHEMBL17754070 | 0.80 | TAF1 (0.60) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17753694 | 0.80 | TAF1 (0.60) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17754066 | 0.79 | BRD9 (0.62) | BRD9TAF1CECR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |